Literature DB >> 10223184

Resistance of HBL100 human breast epithelial cells to vitamin D action.

A Agadir1, G Lazzaro, Y Zheng, X K Zhang, R Mehta.   

Abstract

Vitamin D analogs are effective inhibitors of breast cancer cell growth, but many breast cancer cell lines show various degrees of resistance to the growth inhibitory effect of vitamin D. In this study, we investigated the mechanism of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] resistance of the human breast epithelial cell line HBL100, which had been immortalized by Simian virus 40 (SV40) large T antigen. We determined the expression, DNA binding and transactivation activity of vitamin D3 receptor (VDR) in HBL100 and a vitamin D-sensitive ZR75-1 breast cancer cell line. Western blot analysis revealed a comparable expression of VDR gene in both cell lines. However, gel retardation assays demonstrated nuclear proteins from ZR75-1 cells but not from HBL100; cells expressed a 9-fold increase in the binding activity with a vitamin D response element (VDRE). Using a transient transfection assay, we showed that the VDRE was activated by 8-fold in ZR75-1. However, in HBL100 cells there was no activation observed in response to 1,25(OH)2D3. On the other hand, co-transfection of a VDR expression vector could restore 1,25(OH)2D3-induced VDRE transcription in HBL100 cells. Moreover, stable expression of VDR in HBL100 cells resulted in enhanced sensitivity of the cells to the growth inhibitory effect of 1,25(OH)2D3. Since CV-1 cells express very little endogenous VDR, the interactions of VDR and large T antigen were carried out in these cells. By transient co-transfection, we observed that expression of the large T antigen strongly inhibited 1,25(OH)2D3-induced VDRE transcriptional activity in a dose-dependent fashion in CV-1 cells. At 120 ng VDR concentration, the inhibition was completely reversed. Thus the loss of the growth inhibitory effect of vitamin D3 in HBL100 cells may be caused by the expression of the large T antigen in the cells, and provide further evidence that VDR is required for efficient growth inhibition by vitamin D3.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223184     DOI: 10.1093/carcin/20.4.577

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

Review 1.  New vitamin D analogs as potential therapeutics in melanoma.

Authors:  Paulina Szyszka; Michal A Zmijewski; Andrzej T Slominski
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

2.  Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells.

Authors:  Belinda Byrne; JoEllen Welsh
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-24       Impact factor: 4.292

Review 3.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

Review 4.  Cellular and molecular effects of vitamin D on carcinogenesis.

Authors:  JoEllen Welsh
Journal:  Arch Biochem Biophys       Date:  2011-11-09       Impact factor: 4.013

5.  Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway.

Authors:  Carly M Kemmis; JoEllen Welsh
Journal:  J Cell Biochem       Date:  2008-11-01       Impact factor: 4.429

6.  A histone methyltransferase is required for maximal response to female sex hormones.

Authors:  Tobias Carling; Keun-Cheol Kim; Xiao-Hong Yang; Jian Gu; Xiao-Kun Zhang; Shi Huang
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 7.  The impact of vitamin D in breast cancer: genomics, pathways, metabolism.

Authors:  Carmen J Narvaez; Donald Matthews; Erika LaPorta; Katrina M Simmons; Sarah Beaudin; JoEllen Welsh
Journal:  Front Physiol       Date:  2014-06-13       Impact factor: 4.566

8.  Calcitriol and Calcidiol Can Sensitize Melanoma Cells to Low⁻LET Proton Beam Irradiation.

Authors:  Ewa Podgorska; Agnieszka Drzal; Zenon Matuszak; Jan Swakon; Andrzej Slominski; Martyna Elas; Krystyna Urbanska
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.